Allsup Veterans Appeals Advocating For Veterans Amid Record VA Disability Claims And Ongoing Backlog
Brett Buchanan, U.S. Army veteran and director of Allsup Veterans Appeals
Belleville, Illinois, May 30, 2025 (GLOBE NEWSWIRE) -- In honor of National Military Appreciation Month this May, Allsup, a nationwide provider of disability benefits assistance, and its Allsup Veterans Appeals℠ (AVA) acknowledges the sacrifices of veterans and active-duty service members, reaffirming its commitment to securing the benefits they've earned due to the increasing backlog and complexity of the VA disability appeal process.
The Veterans Benefits Administration (VBA) processed more than 2.5 million disability compensation and pension claims in fiscal year 2024—a 27% increase over 2023 and the highest volume in the history of the U.S. Department of Veterans Affairs (VA). This continued surge highlights the growing complexity of the claims and appeals system, emphasizing the critical need for expert guidance to help veterans secure the full benefits they've earned through service.
This volume of claims not only reflects increased filings by veterans, but also contributes directly to the rising number of appeals. As of May 2025, the VA reported more than 877,000 pending disability claims, including over 201,000 rating-related claims delayed beyond 125 days—highlighting the urgent and escalating challenge veterans face in navigating a complex and overwhelmed system.
'The VA disability claims and appeals process is difficult to navigate and extremely congested,' said Brett Buchanan, U.S. Army veteran and director of Allsup Veterans Appeals. 'Veterans shouldn't have to navigate this alone. Our team of VA-accredited Claims Agents is here to guide them through every step in their appeals, ensuring they receive the benefits they've rightfully earned.'
Among new recipients of VA disability compensation in 2024, tinnitus remained the most frequently awarded service-connected condition, followed closely by musculoskeletal and hearing-related impairments. These top conditions contributed to a substantial portion of the 3.26 million total service-connected disabilities awarded during the year, according to the U.S. Department of Veterans Affairs Annual Benefits Report. In response to the increasing complexity and volume of these claims, AVA's VA-accredited Claims Agents offer veterans a strategic edge and can assist in the following areas:
Veterans who are denied service connection for a disability.
Veterans who need to determine the best path for their VA appeal.
Veterans who need a Higher-Level Review.
Veterans who must file a Supplemental Claim.
Veterans who need to appeal to the Board of Veterans' Appeals.
Veterans who must file a Notice of Disagreement.
For veterans navigating both VA and SSDI claims, Allsup provides expert support to help them receive the full range of benefits available through their military service and employment.
If you or a veteran you know has questions about VA disability benefits, please call 888-372-1190 or visit AllsupVeteransAppeals.com.
ABOUT ALLSUP Allsup and its subsidiaries provide nationwide Social Security disability, veterans disability appeal, disability financial solutions, return to work, and healthcare benefits services for individuals, their employers and insurance carriers. Allsup professionals deliver specialized services supporting people with disabilities and seniors so they may lead lives that are as financially secure and as healthy as possible. Founded in 1984, the company is based in Belleville, Illinois, near St. Louis. Learn more at AllsupVeteransAppeals.com and follow https://www.facebook.com/allsupveteransappeals
Attachment
Brett Buchanan, U.S. Army veteran and director of Allsup Veterans Appeals
CONTACT: Rebecca Ray Allsup (618) 236-5065 r.ray@allsup.com Laura C. Sala Allsup (618) 409-7079 L.Sala@allsup.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA ® to Bladder Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region and one of the first in the U.S. to provide treatment with ANKTIVA ® (nogapendekin alfa inbakicept-pmln) to a veteran with bladder cancer. ANKTIVA, the first of its kind immune-boosting, lymphocyte stimulating agent, is approved by the U.S. Food and Drug Administration (FDA) in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). A 2024 study found military exposure to carcinogenic agents was associated with a higher risk for bladder cancer among veterans, making this treatment especially vital for those at the VA. Nationally recognized urologic oncologists at the Houston VA, Dr. Jeffrey Jones and Dr. Jennifer Taylor, were instrumental in bringing this novel treatment to veterans. They are strong advocates for advancing care for those battling bladder cancer. In addition, Dr. Jones, who is also affiliated with Baylor College of Medicine, led efforts to enroll the facility in ImmunityBio's Expanded Access Program (EAP) for rBCG. 'We are honored to see ANKTIVA reaching our nation's veterans,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Drs. Jones' and Taylor's leadership and commitment to innovation are exactly what's needed to expand access to transformative treatments like ANKTIVA across the VA system. This milestone at DeBakey underscores the real-world impact of our mission.' About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15Rα, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA, which confers stability and longer half-life than recombinant or native IL-15, mimics the natural biological properties of the membrane-bound IL-15Rα, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for use in the United States with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors. For more information, visit (Founder's Vision) and About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, treatment of patients at VA Medical Centers and in certain geographic locations and potential implications to be drawn therefrom, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding commercial launch execution, success and timing and market access initatives, (iii) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (iv) whether clinical trials will result in registrational pathways and the risks, (v) whether clinical trial data will be accepted by regulatory agencies, (vi) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vii) potential delays in product availability and regulatory approvals, (viii) ImmunityBio's ability to retain and hire key personnel, (ix) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (x) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xi) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof.
Yahoo
3 days ago
- Yahoo
Cummings fine-tunes Hellhound drone for Golden Dome mission
Cummings Aerospace unveiled a variant of its Hellhound drone designed to meet homeland defense missions at the Space and Missile Defense Symposium in Huntsville, Alabama, this week. The company is taking its S3 variant and beefing it up into a new S4 variant to take on air defense missions, particularly countering drone threats, that could fit within the framework of President Donald Trump's homeland missile defense shield dubbed Golden Dome. The turbojet-powered, 3D-printed Hellhound S3 drone can carry a variety of payloads, and the company is putting that version forward as a loitering munition option for a competition that the U.S. Army is planning to kick off this year. The S4 variant, designed to take on Golden Dome mission sets, is a scaled-up version of the S3 that adopts its modular architecture such as the removable nose that allows the unmanned aerial system to shift from countering drones to intelligence, surveillance and reconnaissance or serving as a weapon itself like a low-cost cruise missile, according to Sheila Cummings, the company's CEO. The S4 is 'really a multimission capability as well as a multilaunch platform capability,' she added, 'so ground-based is kind of the primary, but then the airframe and launch canister can support both an air- and sea-based launch.' 'Mobility and multimission capability are obviously paramount to any sort of layered approach for Golden Dome,' she said. While the S3 variant is roughly 12 to 14 pounds, depending on the payload, the S4 falls in the 45-pound range. But the majority of the capability uses the same software, additive manufacturing techniques, 3D-printed materials and other commercial-off-the-shelf parts. The S4 is in the engineering development phase and the company is building prototypes. The plan is to go into flight tests with the capability from as early as this fall through next spring, Cummings said. Like the S3 manufacturing strategy, the S4 design also takes into account the reality that it will need to be manufactured at a large scale. The military is changing the way it acquires weapon systems and, in many cases, requires companies to prove they can build systems at scale as part of competitive acquisitions. Historically, a weapon system might be chosen for its performance on the battlefield without much attention paid to the amount of work it would take to build a system or even how stable the supplier base was. The Huntsville-based company chose a space next door to Redstone Arsenal, Alabama, home to the program office and testing and development for Army aviation, in 2021 and designed and built a facility intended to produce large numbers of the drones. A large portion of the Hellhound air vehicle is made using commercially available 3D printers in-house and buying commercially available standard parts that are not unique to just a few suppliers, Cummings said. 'If you think about low-cost solutions — that's part of the strategy — is we have to design something that we can get screws from multiple vendors, we can get 3D print material from multiple vendors,' she said. 'We talk about exquisite payloads, that's a different challenge, but electronics, we have to make sure we can source them from multiple vendors.' For the Huntsville facility, Cummings said her goal is to produce at least 100 S3 air vehicles a month. 'The same distributed manufacturing approach that we have considered for the Hellhound S3 through our supplier partners is the same approach that we're looking to take with S4 again,' Cummings said, such as, 'the combination of U.S. and international partners [and] licensing agreements for the vehicle design, whether it be with the government or with industry partners, in order to meet the production demand.' The company is 'well suited to bring forward the solution set for Golden Dome as part of that layered defensive strategy,' she said. 'Cummings Aerospace was built on missile defense programs. That's how we first got started, and so we have, over the last 16 years, contributed to almost every interceptor, sensor or [command-and-control] program within the missile defense portfolio.' Solve the daily Crossword
Yahoo
3 days ago
- Yahoo
Mortgage and refinance interest rates today, August 8, 2025: It could be a good time to lock in a rate
Mortgage rates have dropped this week. According to Freddie Mac, the national average 30-year rate is down to 6.63% and the 15-year fixed mortgage rate has gone down ten basis points to 5.75% this week. While mortgage rates have declined this week, rates are not set to drop below the 6% range this year. If you are looking to buy a house in 2025, this could be a good time to lock in a mortgage while rates are low. Just make sure to choose a mortgage lender with a rate buydown option. With an interest rate buydown program, you can re-lock your interest rate before buying a house if market rates decrease. Learn more: When will mortgage rates go down? Rates are still higher than this time last year. Current mortgage rates Here are the current mortgage rates, according to the latest Zillow data: 30-year fixed: 6.63% 20-year fixed: 6.03% 15-year fixed: 5.75% 5/1 ARM: 6.90% 7/1 ARM: 6.86% 30-year VA: 6.03% 15-year VA: 5.47% 5/1 VA: 6.03% Remember, these are the national averages and rounded to the nearest hundredth. Current mortgage refinance rates These are today's mortgage refinance rates, according to the latest Zillow data: 30-year fixed: 6.45% 20-year fixed: 6.10% 15-year fixed: 5.71% 5/1 ARM: 7.23% 7/1 ARM: 7.21% 30-year VA: 6.06% 15-year VA: 6.01% 5/1 VA: 6.00% Again, the numbers provided are national averages rounded to the nearest hundredth. Mortgage refinance rates are often higher than rates when you buy a house, although that's not always the case. Learn more: Want to refinance your mortgage? Here are 7 home refinance options. Refinance interest rates Up Next Up Next Free mortgage calculator Your mortgage rate plays a large role in how much your monthly payment will be. Use this mortgage calculator to see how your mortgage amount, rate, and term length will impact your monthly payments: To get an even more detailed look at your potential monthly payment, use our Yahoo Finance mortgage calculator. It also factors in your homeowners insurance, property taxes, mortgage insurance, and HOA fees. How mortgage interest rates work A mortgage interest rate is a fee for borrowing money from your lender, expressed as a percentage. You can choose from two types of rates: fixed or adjustable. A fixed-rate mortgage locks in your rate for the entire life of your loan. For example, if you get a 30-year mortgage with a 6% interest rate, your rate will stay at 6% for the entire 30 years unless you refinance or sell. An adjustable-rate mortgage locks in your rate for a predetermined amount of time and then changes it periodically. Let's say you get a 7/1 ARM with an introductory rate of 6%. Your rate would be 6% for the first seven years, then the rate would increase or decrease once per year for the last 23 years of your term. Whether your rate goes up or down depends on several factors, such as the economy and housing market. At the beginning of your mortgage term, most of your monthly payment goes toward interest. Your monthly payment toward mortgage principal and interest stays the same throughout the years — however, less and less of your payment goes toward interest, and more goes toward the mortgage principal or the amount you originally borrowed. Learn more: Adjustable-rate vs. fixed-rate mortgages Which mortgage term length should you get? A 30-year fixed-rate mortgage is a good choice if you want a lower mortgage payment and the predictability that comes with having a fixed rate. Just know that your rate will be higher than if you choose a shorter term, and you will pay significantly more in interest over the years. You might like a 15-year fixed-rate mortgage if you want to pay off your home loan quickly and save money on interest. These shorter terms come with lower interest rates, and since you're cutting your repayment time in half, you'll save a lot in interest in the long run. But you'll need to be sure you can comfortably afford the higher monthly payments that come with 15-year terms. Read more: How to decide between a 15-year and 30-year fixed-rate mortgage Typically, an adjustable-rate mortgage could be good if you plan to sell before the introductory rate period ends. Adjustable rates usually start lower than fixed rates, then your rate will change after a predetermined amount of time. However, 5/1 and 7/1 ARM rates have similar to (or even higher than) 30-year fixed rates recently. Before getting an ARM just for a lower rate, compare your rate options from term to term and lender to lender. Are mortgage rates decreasing? Yes and no. Mortgage rates have decreased over the last couple of weeks more than they have all summer, but rates are still firmly planted between 6% and 7% and are set to stay that way. The 30-year and 15-year fixed rates are also higher than this time last year. Mortgage interest rates will probably stay relatively high for the rest of the year. The latest Fannie Mae and Mortgage Bankers Association (MBA) forecasts predict that mortgage rates will stay at or above 6% even through 2026. Mortgage interest rates today: FAQs What are mortgage interest rates doing today? According to Freddie Mac, the national average 30-year mortgage rate is down nine basis points to 6.63%, and the average 15-year mortgage rate has decreased by 10 basis points to 5.75%. How low will mortgage rates go in 2025? According to its July forecast, the MBA expects the 30-year mortgage rate to be 6.8% in Q3 2025 and 6.7% by the end of the year. Fannie Mae puts the 30-year rate at 6.5% in Q3 and 6.4% in Q4. How high could mortgage rates go by 2025? Mortgage rates will probably decrease in 2025 rather than increase. However, those declines are expected to be minor.
